GENERATION BIO
Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies... to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.
GENERATION BIO
Industry:
Biotechnology Genetics Health Care
Founded:
2016-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.generationbio.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
460.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Apton Biosystems
Apton Biosystems develops an optical system designed for sequencing and protein detection.
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Homology Medicines
Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.
Kytopen
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Strands Hair Care
Strands Hair Care is a provider of personalized hair care products using real biological data.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Foresite Capital
Foresite Capital investment in Series C - Generation Bio
T. Rowe Price
T. Rowe Price investment in Series C - Generation Bio
Deerfield
Deerfield investment in Series C - Generation Bio
Wellington Management
Wellington Management investment in Series C - Generation Bio
Farallon Capital Management
Farallon Capital Management investment in Series C - Generation Bio
Fidelity
Fidelity investment in Series C - Generation Bio
Invus
Invus investment in Series C - Generation Bio
Atlas Venture
Atlas Venture investment in Series C - Generation Bio
Casdin Capital
Casdin Capital investment in Series C - Generation Bio
Casdin Capital
Casdin Capital investment in Series B - Generation Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-10 | Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer |
Official Site Inspections
http://www.generationbio.com Semrush global rank: 2.61 M Semrush visits lastest month: 6.65 K
- Host name: generationbio.tempurl.host
- IP address: 64.176.206.3
- Location: Andover United States
- Latitude: 42.6508
- Longitude: -71.1607
- Metro Code: 506
- Timezone: America/New_York
- Postal: 01810
More informations about "Generation Bio"
About Us - generationbio.com
About Us Leading science, breaking barriersExperienced leadership fuels innovative science. With expertise across disciplines, our team is shaping the futur ...See details»
Generation Bio - LinkedIn
Generation Bio is a biotechnology company changing what is possible for people living with T cell-driven autoimmune diseases. The company is developing a new modality of therapeutics …See details»
Generation Bio - Crunchbase Company Profile
Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable …See details»
Generation Bio - 2025 Company Profile & Team - Tracxn
Generation Bio - Developer of gene therapies for rare liver and eye diseases. Public Company. Raised a total funding of $236M over 3 rounds from 11 investors.See details»
Generation Bio Co. - BIO International Convention 2025
We are a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. Our strategy is to discover, develop, and commercialize …See details»
Generation Bio Co Company Profile - Overview - GlobalData
Generation Bio Co (Generation Bio) is a biotechnology company. It focuses on the development of non-viral genetic medicines. Its primary platforms include a cell-targeted lipid nanoparticle …See details»
Generation Bio Co. - Executive Bio, Top Executies, and Transitions ...
Kevin joined Generation Bio in 2019 and has played a critical role in leading and establishing the Finance organization. Kevin brings 15 years of Accounting and Finance leadership across …See details»
Generation Bio Changing what’s possible for People …
Our T cell-selective ctLNP delivers siRNA to potently modulate T cell function and avoids off-target uptake by other immune cells and clearance organs, such as the liver and spleen.See details»
Generation Bio - Work in biotech
Generation Bio is developing a new class of genetic medicines. Using their proprietary non-viral genetic medicine platform, Generation Bio is creating scalable and redosable medicines. The …See details»
Investor Relations - Generation Bio
Jun 4, 2025 The Investor Relations website contains information about Generation Bio's business for stockholders, potential investors, and financial analysts.See details»
Generation Bio to Present at the 2025 Jefferies Global
May 28, 2025 Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference May 28, 2025 06:59 ET | Source: Generation Bio Co.See details»
Generation Bio jettisons 90% of employees, including R&D org
1 day ago Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find cash to take its lipid nanoparticle tech further.See details»
Our Focus - generationbio.com
Our Focus T cells are the master regulators of the immune systemAnd they are at the heart of tissue damage in a number of autoimmune diseases. Autoreactive ...See details»
Generation Bio Announces New Data for Its Novel ctLNP Delivery …
Jun 30, 2025 Generation Bio’s proprietary ctLNP is a modular system engineered to deliver genetic medicine cargoes to a range of cell types, potentially opening new tissues for …See details»
Generation Bio soars as it explores strategic alternatives
1 day ago Generation Bio (GBIO) soars 45% after announcing a strategic review exploring mergers, acquisitions, or sales.See details»
Careers - generationbio.com
Careers Innovative science fueled by talent and a commitment to inclusivityEvery team member adds to our strength, shaping a community where creativity, col ...See details»
Generation Bio Reports Recent Business Highlights and First …
May 7, 2025 This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable …See details»
News Releases - Generation Bio
Jul 18, 2025 The Investor Relations website contains information about Generation Bio's business for stockholders, potential investors, and financial analysts.See details»
Generation Bio to Present at American Society of Gene & Cell …
The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places …See details»
Our Science | generationbio.com
Cell-targeted lipid nanoparticle (ctLNP): a breakthrough technology for targeted delivery Our proprietary ctLNP technology enables selective access to T cells and precise target inhibition …See details»